---
figid: PMC9649345__gr3
pmcid: PMC9649345
image_filename: gr3.jpg
figure_link: /pmc/articles/PMC9649345/figure/f0015/
number: Fig. 3
figure_title: ''
caption: 'Angelica Yinzi suppresses the production of inflammatory cytokines via the
  MAPKs/NF-κB pathway. (A-B) The Western blot analysis of p-p38, p-ERK, p-JNK, p65,
  and p-p65 proteins expressions. (C) The p-p65 expression in the skin tissue based
  on the immunohistochemical staining at magnification × 200. (D-E) The mRNA levels
  of TNF-α and IL-1β in each group. Data are expressed as the mean ± SD. (n = 3).
  ##p < 0.01, vs. the control group, *p < 0.05 and **p < 0.01 vs. the DNCB group.'
article_title: Angelica Yinzi alleviates 1-chloro-2,4-dinitrobenzene-induced atopic
  dermatitis by inhibiting activation of NLRP3 inflammasome and down-regulating the
  MAPKs/NF-kB signaling pathway.
citation: Wei Liu, et al. Saudi Pharm J. 2022 Oct;30(10):1426-1434.
year: '2022'

doi: 10.1016/j.jsps.2022.07.003
journal_title: 'Saudi Pharmaceutical Journal : SPJ'
journal_nlm_ta: Saudi Pharm J
publisher_name: Elsevier

keywords:
- Angelica Yinzi
- Atopic dermatitis
- MAPK
- NLRP3
- Inflammation

---
